Riociguat, an FDA-approved sGC activator, has demonstrated efficacy in reducing pulmonary arterial pressure and improving exercise capacity in PAH patients by enhancing endothelial function and reducing right ventricular afterload [46]. This evidence concerns the gene SGCB and pulmonary arterial hypertension.